Abstract
First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have